Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

671 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endotoxins and Non-Alcoholic Fatty Liver Disease.
Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M, Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Kessoku T, et al. Among authors: iwaki m. Front Endocrinol (Lausanne). 2021 Oct 29;12:770986. doi: 10.3389/fendo.2021.770986. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34777261 Free PMC article. Review.
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).
Ozaki A, Yoneda M, Kessoku T, Iwaki M, Kobayashi T, Honda Y, Ogawa Y, Imajo K, Sakai E, Taguri M, Yamanaka T, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Ozaki A, et al. Among authors: iwaki m. Contemp Clin Trials Commun. 2019 Dec 31;17:100516. doi: 10.1016/j.conctc.2019.100516. eCollection 2020 Mar. Contemp Clin Trials Commun. 2019. PMID: 31956725 Free PMC article.
Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
Ozaki A, Kessoku T, Iwaki M, Kobayashi T, Yoshihara T, Kato T, Honda Y, Ogawa Y, Imajo K, Higurashi T, Yoneda M, Taguri M, Yamanaka T, Ishiki H, Kobayashi N, Saito S, Ichikawa Y, Nakajima A. Ozaki A, et al. Among authors: iwaki m. Trials. 2020 Jun 1;21(1):453. doi: 10.1186/s13063-020-04385-0. Trials. 2020. PMID: 32487150 Free PMC article.
The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
Misawa N, Higurashi T, Takatsu T, Iwaki M, Kobayashi T, Yoshihara T, Ashikari K, Kessoku T, Fuyuki A, Matsuura T, Ohkubo H, Usuda H, Wada K, Naritaka N, Takei H, Nittono H, Matsumoto M, Honda A, Nakajima A, Camilleri M. Misawa N, et al. Among authors: iwaki m. Aliment Pharmacol Ther. 2020 Sep;52(5):821-828. doi: 10.1111/apt.15950. Epub 2020 Jul 20. Aliment Pharmacol Ther. 2020. PMID: 32687674 Clinical Trial.
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Kessoku T, et al. Among authors: iwaki m. Lancet Gastroenterol Hepatol. 2020 Nov;5(11):996-1007. doi: 10.1016/S2468-1253(20)30216-8. Epub 2020 Aug 15. Lancet Gastroenterol Hepatol. 2020. PMID: 32805205 Clinical Trial.
Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.
Kessoku T, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Ogawa Y, Imajo K, Saigusa Y, Yamamoto K, Yamanaka T, Usuda H, Wada K, Yoneda M, Saito S, Nakajima A. Kessoku T, et al. Among authors: iwaki m. BMJ Open. 2020 Sep 9;10(9):e037961. doi: 10.1136/bmjopen-2020-037961. BMJ Open. 2020. PMID: 32907904 Free PMC article.
Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype.
Kessoku T, Kobayashi N, Yoneda M, Kasai Y, Ozaki A, Okubo N, Iwaki M, Kobayashi T, Yoshihara T, Kurita Y, Honda Y, Tokuhisa M, Ishiki H, Hibiya T, Fujii S, Nakajima A, Ichikawa Y. Kessoku T, et al. Among authors: iwaki m. Front Oncol. 2020 Sep 25;10:555963. doi: 10.3389/fonc.2020.555963. eCollection 2020. Front Oncol. 2020. PMID: 33102220 Free PMC article.
Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Imajo K, Honda Y, Kobayashi T, Nagai K, Ozaki A, Iwaki M, Kessoku T, Ogawa Y, Takahashi H, Saigusa Y, Yoneda M, Kirikoshi H, Utsunomiya D, Aishima S, Saito S, Nakajima A. Imajo K, et al. Among authors: iwaki m. Clin Gastroenterol Hepatol. 2022 Apr;20(4):908-917.e11. doi: 10.1016/j.cgh.2020.12.016. Epub 2020 Dec 17. Clin Gastroenterol Hepatol. 2022. PMID: 33340780 Free article.
Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease.
Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Maeda A, Tanaka Y, Nakajima S, Ohno H, Usuda H, Kawanaka M, Kawaguchi T, Torimura T, Kage M, Hyogo H, Takahashi H, Eguchi Y, Aishima S, Wada K, Kobayashi N, Sumida Y, Saito S, Nakajima A. Iwaki M, et al. J Gastroenterol Hepatol. 2021 Aug;36(8):2275-2284. doi: 10.1111/jgh.15487. Epub 2021 Mar 29. J Gastroenterol Hepatol. 2021. PMID: 33709477
671 results